This paper reviews the literature on KRAS G12C mutations, with a focus on the epidemiology and prognosis of KRAS G12C within CRC and the barriers that remain to the incorporation of KRAS G12C inhibitors into clinical practice in CRC. Here, KRAS is linked to colorectal carcinoma.